ST12
Version 1.18f657e7 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | ST12 |
| Synonyms | Not available |
| SMILES | Not available |
| Formula | Not available |
| M.Wt | Not available |
| Purity | 98% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Qin P, Qin Q, Hao Y, et al. Enhanced antitumor immunity of mRNA vaccines by bioorthogonal-like delayed activation of exogeneous STING. Nature Biotechnology. 2026. |
ST12 is a lipid-conjugated DMXAA prodrug designed for temporally controlled STING activation in mRNA vaccine formulations. Its structure integrates a mouse-specific STING agonist, a biodegradable ester linker, an RNA-interacting tertiary amine domain, and two hydrophobic tails. When incorporated as a partial replacement for SM-102, ST12 preserves early antigen mRNA translation and subsequently releases DMXAA to activate STING. This delayed activation supports localized type I interferon signaling, enhanced antigen-specific CD8-positive T-cell responses, and improved antitumor immunity. In preclinical OVA and HPV tumor models, ST12-based Syn-STING vaccines suppressed tumor growth and prolonged survival. ST12 remains a preclinical research lipid developed specifically around DMXAA-sensitive STING systems.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →